Personalized Medicine: Setting the stage for a new era
in breast cancer therapy
Dr. Bryan Schneider
Friday, May 4, 2018
Rushmore Plaza Holiday Inn, Rapid City, SD
Breast cancer survivors attend at no cost, but must RSVP using the ticket link below.
Appetizers and cash bar
More so now than ever, when doctors decide how to attack a cancer, they are arming themselves with a wealth of knowledge about the specific molecular and genetic makeup of their patient’s tumor.
Many researchers and cancer centers are already embracing this personalized approach to cancer care. One of the major goals of personalized medicine – give patients the treatments that are most likely to work on their particular cancer with fewer harmful side effects.
“My career is defined by a commitment to translational and clinical implementation of personalized medicine in cancer care. I am an Associate Professor of Medicine at the Indiana University Melvin and Bren Simon Cancer Center and serve as the Director of the IU Health Precision Genomics Program, which uses next generation sequencing to identify novel therapeutics for patients without standard therapeutic options. My time is devoted to caring for breast cancer patients as a Medical Oncologist and leading laboratory research work resulting in the identification of several biomarkers that predict which patients might suffer severe side effects from chemotherapy drugs before they ever receive the drug.”
Dr. Bryan Schneider has identified several biomarkers that predict which patients might suffer severe side effects from chemotherapy.